BPC-157 (Body Protection Compound 157) represents one of the most extensively researched synthetic peptides in preclinical literature, with over 500 peer-reviewed studies indexed on PubMed since 1993. This review covers what that research actually shows, organized by the tissue categories that have received the most published attention.
BPC-157 was first isolated from human gastric juice by Professor Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. The research question: the human stomach is exposed constantly to hydrochloric acid and digestive enzymes yet regenerates with extraordinary efficiency. Sikiric’s hypothesis was that endogenous protective factors must be present in gastric secretions. BPC-157 was the 157th compound tested in this series, first published in Life Sciences in 1993.
Two mechanisms dominate the BPC-157 literature. First, nitric oxide synthesis modulation: multiple published studies document upregulation of eNOS expression in endothelial cell models and in vivo vascular tissue. Second, COX-2 pathway interaction: published data show complex, context-dependent modulatory effects on prostaglandin synthesis that researchers have discussed in relation to BPC-157’s tissue-protective properties across multiple injury types.
GI tissue was the first and remains one of the most extensively studied categories. Published animal model studies have examined BPC-157 in models of gastric ulceration, esophageal reflux injury, short bowel syndrome, experimental inflammatory bowel conditions, and fistula healing — consistently reporting accelerated healing compared to controls across multiple experimental designs.
A 2011 study by Chang et al. (Journal of Applied Physiology) examined BPC-157 in a rat Achilles tendon transection model and reported accelerated collagen organization, improved tensile strength markers, and enhanced vascularization in treated tendons at multiple measurement timepoints.
Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.
In angiogenesis models, published findings include VEGFR2 upregulation and accelerated capillary formation in wound healing contexts. A growing and more recent area examines peripheral nervous system applications: peripheral nerve crush and transection models, spinal cord injury models, and dopamine/serotonin pathway modulation — expanding well beyond the original GI focus.
For informational purposes only. BPC-157 is available through Brava Longevity as a research compound. Not medical advice or dosing guidance.
